Signal The US Inflation Reduction Act and health technology assessment regimes are named as pricing pressure

Summary

NTT DATA identifies a major patent cliff, the United States Inflation Reduction Act and health technology assessment regimes as the converging pricing and access pressures on pharma entering 2026, alongside rising complexity in biologics, cell and gene therapy and antibody-drug conjugates.